Exelixis, FDA Agree On XL184 Cancer Treatment Trial

Armen Hareyan's picture
Advertisement

Exelixis plans a late-stage clinical trial for the dtug XL184 for thyroid cancer treatment and the company has reached agreement with FDA about the trial design.

The company and

Advertisement